Clinical trials: Atorvastatin, completed
Chronic Kidney Disease
Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
Patients with chronic kidney disease (CKD) are high risk for death and cardiac disease is the major cause of death. CKD patients commonly have traditional risk factors for coronary artery disease, such as age, gender…
- Trial name
- NCT02863185
- Testing
- Pitavastatin, Atorvastatin
- Where
- 2 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- Dong-A University
Carotid Atherosclerosis
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers
- Trial name
- MCAT (NCT00804843)
- Testing
- Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers.
- Trial name
- NCT02651753
- Testing
- Lipitor + Lipidil supra, CKD-337
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
Multiple Ascending Dose and DDI Study
Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design.
- Trial name
- NCT03031119
- Testing
- PF-06835919, atorvastatin
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cardiovascular Disorders
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events
In western societies hypercholesterolemia is one of the major and independent factors that predispose to cardiovascular disease and death from them.
- Trial name
- EKVASIS (NCT01770210)
- Testing
- Patients on atorvastatin treatment
- Where
- 17 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Type 2 Diabetes Mellitus
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
- Trial name
- NCT06293742
- Testing
- ECC5004, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eccogene
Kidney Cancer, Renal Cell Carcinoma
Zoledronate With Atorvastatin in Renal Cell Carcinoma
Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases…
- Trial name
- NCT00490698
- Testing
- Zoledronate, Atorvastatin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Obesity, Dyslipidemia
Regulation of Lipoprotein Metabolism in Obese Men
Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS).
- Conditions
- Obesity, Dyslipidemia, Insulin Resistance
- Trial name
- NCT00392717
- Testing
- Atorvastatin, Fish oils
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The University of Western Australia
Healthy
Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions
The purpose of this study is to assess the bioequivalence between Atorvastatin calcium 40 mg of Dr. Reddy's Laboratories Limited, India and Lipitor® 40mg Tablets of Pfizer Ireland Pharmaceuticals in healthy, adult, human subjects…
- Trial name
- NCT01645410
- Testing
- Atorvastatin Calcium Tablets, 40 mg
- Where
- India
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemia
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor.
- Trial name
- CENTAUR (NCT00728910)
- Testing
- Atorvastatin, ABT335, ER Niacin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on…
- Trial name
- CONTROL (NCT02633956)
- Testing
- Obeticholic Acid, Atorvastatin
- Where
- 22 sites in United States
- Volunteers
- 84 people
- Sponsor
- Intercept Pharmaceuticals
Heart Failure
A Study Of The Usage Of Statins In A Community Heart Failure Population
Inflammation and fibrosis may be important contributors to worsening heart failure. As well as lowering cholesterol, statins are also known to reduce inflammatory markers such as C-reactive protein which are elevated in severe…
- Trial name
- NCT00795912
- Testing
- Atorvastatin
- Where
- Ireland
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- St Vincent's University Hospital, Ireland
Heterozygous Familial Hypercholesterolemia
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with…
- Trial name
- ODYSSEY FH II (NCT01709500)
- Testing
- LMT (atorvastatin, simvastatin, or rosuvastatin), alirocumab
- Where
- 24 sites in Czechia, Netherlands and 2 more
- Volunteers
- 249 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin
- Trial name
- NCT06081166
- Testing
- Obicetrapib, Atorvastatin Calcium, Rosuvastatin Calcium
- Where
- Canada
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- NewAmsterdam Pharma
Metabolism Disorder, Lipid, Metabolism Disorder, Glucose
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of…
- Trial name
- XTREME (NCT05238012)
- Testing
- Xuezhikang Capsule, Atorvastatin Calcium Tablets
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Heart Health Research Center
Alagille Syndrome, Atorvastatin
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
To observe the efficacy and safety of atorvastatin on xanthoma in Alagille syndrome through a prospective study.
- Conditions
- Alagille Syndrome, Atorvastatin, Xanthoma
- Trial name
- NCT05488067
- Testing
- atorvastatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Children's Hospital of Fudan University
Atherosclerosis
The Effects of Atorvastatin in Patients With Atherosclerosis
The purpose of the study is to evaluate the effects of Atorvastatin. The investigators want to find out if atorvastatin has other helpful qualities.
- Trial name
- NCT00115817
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital